Europe accuses drug makers of padding healthcare costs
The European Union has accused drug companies of adding billions of dollars to healthcare costs by delaying or blocking the sale of less expensive generic medicines. Patients and healthcare systems in Europe would have saved at least 3 billion euros, or $3.8 billion, from 2000 to 2007—or shaved 5% off the medical bills—if companies had let generics into the market sooner, said Neelie Kroes, the European competition commissioner.
- CFO Exchange: Smartphones Poised to Disrupt Healthcare, Says Topol
- CNO on Hospital Redesign: 'You Can't Over-Communicate'
- How Digital Strategy Shapes Patient Engagement at Boston Children's Hospital
- Half of All Primary Care, Internal Medicine Jobs Unfilled in 2013
- Consumerism Drives Healthcare Branding, Rebranding Efforts
- PA Ranks See 'Phenomenal Growth,' Lack of Diversity
- 3 Traits Personality Assessments Can't Reveal
- Carondelet to Pay $35M to Settle Fraud Allegations
- Some Cancer Hospitals' Quality Data Will Soon Be Public
- Antibiotic Overuse a 'Huge Threat' to Patient Safety, Says CDC